68Ga-labeled NY108 PET Imaging in Patients
Prostatic Cancer
About this trial
This is an interventional diagnostic trial for Prostatic Cancer
Eligibility Criteria
Inclusion Criteria: Patients voluntarily signed informed consent; Age 18-75, male; Patients diagnosed with prostatic cancer confirmed by histopathology or cytology; At least one measurable solid lesion has been examined according RECIST1.1 standard; Patients with biopsy-proven PSMA positive; ECOG score 0~3; Life expectancy of at least 3 months; Exclusion Criteria: Recovery from major trauma (including surgery) within 4 weeks prior to study treatment; Patients with systemic or locally severe infections, or other serious coexisting diseases; Patients with allergies or allergies to any component of the imaging agent or antibody; Patients who cannot perform PET/CT imaging scan; Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines; Patients with autoimmune diseases, including rheumatoid arthritis; Inadequate control of arrhythmias, including atrial fibrillation; Uncontrolled hypertension; Syphilis, HBV, HCV, or HIV positive subjects; Male subjects of reproductive age cannot take effective contraceptive measures; Patients with a history of mental illness or related conditions; Other subjects considered unsuitable by researchers.
Sites / Locations
- Affiliated Hospital of Jiangnan UniversityRecruiting
Arms of the Study
Arm 1
Experimental
68Ga-Anti-PSMA mAbs